Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 70 of 100, showing 5 Applications out of 500 total, starting on record 346, ending on 350

# Protocol No Study Title Investigator(s) & Site(s)

346.

ECCT/17/05/04   Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost
    A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WALTER REED KERICHO
 
View

347.

ECCT/17/08/01   A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults
    A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines.   
Principal Investigator(s)
1. Philip Bejon
Site(s) in Kenya
KEMRI Kilifi
 
View

348.

ECCT/17/05/02   The Anza Mapema Study
    Expanding test and treat for HIV prevention in MSM in Kisumu, Kenya: The Anza Mapema Study   
Principal Investigator(s)
1. Fredrick Odhiambo Otieno
Site(s) in Kenya
Anza Mapema Study Clinic
 
View

349.

ECCT/17/03/02   The Edoxaban Hokusai VTE PEDIATRICS Study
    A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)   
Principal Investigator(s)
1. Bernhards Ragama Ogutu Ragama
Site(s) in Kenya
1. Gertrudes Hospital (Nairobi City county)
2. Mater Hospital (Nairobi City county)
 
View

350.

ECCT/17/03/05   HOPE Sickle Cell Disease Clinical Study
    A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease   
Principal Investigator(s)
1. Videlis Nduba
2. Jessie Nyokabi Githanga
Site(s) in Kenya
1. Gertrude\'s Children\'s Hospital (Nairobi City county)
2. Strathmore University Medical Center (Nairobi City county)
3. KEMRI CRDR Clinical Research clinic at Chandaria Health Center (Nairobi City county)
4. KEMRI Kondele Childrens Hospital Center for Clinical Research (Kisumu county)
5. KEMRI Clinical Research Center at Siaya County Referral Hospital (Siaya county)
 
View